F. Hoffmann-La Roche AG


About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche retains sole responsibility for content © 2018 F. Hoffmann-La Roche AG. All trademarks used or mentioned in this release are protected by law.

1 May 2017 - 30 April 2018

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 May 2017 - 30 April 2018 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

114 54.25

Outputs by subject (FC)

Subject AC FC
Chemistry 33 20.79
Life Sciences 80 33.27
Physical Sciences 1 0.02

Highlight of the month

How to improve cancer immunotherapy

© Ariel Skelley/DigitalVision/Getty

© Ariel Skelley/DigitalVision/Getty

Blocking a critical growth factor in a tumour’s microenvironment could boost the cancer-killing potential of immunotherapy.

An international team led by scientists from Genentech, a Roche subsidiary, examined tumour samples from hundreds of patients with advanced-stage urinary cancers. All of the patients had received atezolizumab, a drug that blocks an ‘off switch’ signal that tumours use to ward off an immune onslaught, but only 22 per cent of them responded favourably.

The researchers found a strong association between the lack of drug response and the presence of cells in the tumour surroundings that expressed high levels of transforming growth factor β (TGFβ), a protein that keeps cancer-killing T-cells from reaching the tumour core.

In a mouse model of breast cancer, delivering a drug that targets TGFβ along with a mouse version of atezolizumab allowed more T-cells to penetrate the tumours, triggering tumour shrinkage. The findings, described in Nature, suggest that this dual therapeutic strategy merits further clinical testing in patients.

Supported content

  1. Nature 554, 544–548 (2018). doi: 10.1038/nature25501

View the article on the Nature Index

See more research highlights from F. Hoffmann-La Roche AG

More research highlights from F. Hoffmann-La Roche AG

1 May 2017 - 30 April 2018

International vs. domestic collaboration by FC

  • 7.98% Domestic
  • 92.02% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the fractional count (FC), which is listed in parentheses.

Affiliated joint institutions and consortia

Return to institution outputs